News Archive

/static/apps/cms/news/1743/Untitled-1.jpg

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

March 31, 2026 / Experimental Pathology

Small cell lung cancer (SCLC) is a highly aggressive cancer that evades the immune system by suppressing MHC-I, a molecule that normally helps T cells recognize and attack cancer cells. Although this loss of MHC-I should make SCLC susceptible to natural killer (NK) cells, which target such cells, NK cells are largely missing from the tumor environment in patients, limiting this potential immune response.

FULL STORY
/static/apps/cms/news/1740/Gabrielle Rozumek headshot.jpg

MCP Student Gabbi Rozumek becomes Dr. Gabrielle M. Rozumek

March 30, 2026 / Phd Program

The Department of Pathology at the University of Michigan proudly celebrates the achievements of our graduating scholars, whose scientific curiosity, commitment, and resilience exemplify our department's mission. Among them is Gabrielle Rozumek, PhD, whose journey through the Molecular & Cellular Pathology (MCP) Graduate Program reflects both the spirit of inquiry that drives pathology and the profound humanity that underpins our field.

FULL STORY

Arul Chinnaiyan awarded 13th annual Harrington Prize

March 27, 2026 /
Arul M. Chinnaiyan was awarded the 13th annual Harrington Prize for Innovation in Medicine, recognizing his groundbreaking identification of a gene fusion that drives prostate cancer. Chinnaiyan is the director of the Michigan Center for Translational Pathology and the S.P. Hicks Endowed Professor of Pathology at Michigan Medicine. The award was given jointly with Charles L. Sawyer, Marie-Josée and Henry R. Kravis Chair in Human Oncology
FULL STORY

Match Day 2026!

March 20, 2026 / Residents

It's Match Day! Welcome to the eight new residents joining the U-M Pathology Residency Program.

FULL STORY
/static/apps/cms/news/1730/images/banners/Bernard Lo Header.png

Early Career Insights in Immunology: Dr. Lo’s Approach to Complex Diseases

March 18, 2026 / Gi Research
Dr. Bernard Lo, PhD, Research Investigator, did not set out to study gut immunity, nor did he anticipate that his work would one day intersect with some of the most pressing questions in cancer immunotherapy. Growing up in Vancouver, British Columbia, Lo’s early academic life was rooted close to home. He completed both his undergraduate and doctoral training at the University of British Columbia, where he discovered his interest in immunolo
FULL STORY
/static/apps/cms/news/1737/LukacsKunkel.jpg

Opsidio, LLC Acquired by Insmed, Advancing Anti-SCF Therapy: From Discovery to Clinical trials

March 13, 2026 / Research

Opsidio, LLC—co-founded by Nicholas W. Lukacs, PhD, Steven Kunkel, PhD, and Cory Hogaboam, PhD—has been acquired by Insmed, which plans to advance the company’s investigational monoclonal antibody INS1148 into Phase 2 studies for interstitial lung disease and moderate-to-severe asthma.

FULL STORY
/static/apps/cms/news/1723/images/banners/Yi Bao header.png

Where Passion Meets Discovery: Yi Bao, PhD’s Path to Research Investigator

March 3, 2026 / Faculty Spotlight
“I watched a family member go through chemotherapy for lung cancer. It was incredibly painful for them, and ultimately, the treatment only extended their life for a few months. A few years ago, I watched them pass away from the disease. That experience drove me to pursue a PhD in cancer biology.” Yi Bao, PhD, completed his undergraduate education at South China Agricultural University and then earned a Master of Science degree at the
FULL STORY